Andres-Martin received her Ph.D. from the University of Salamanca in Spain, studying cancer and rare diseases. She then served as a postdoc at Weill Cornell Medicine, where she studied neurodegeneration and adult stem cells. In 2015, she received the NYSCF–Druckenmiller postdoctoral fellowship, which supported her research on the mechanisms that underlie increased disease risk due to stem cell dysfunction.
Andres-Martin is the founding PI of the JAX-NYSCF Women’s Reproductive Cancers Initiative, where she leads the cancer program. Her laboratory has built a stem cell-based human modeling platform of patient-specific tumor avatars known as organoids, and uses it to test tumor-specific sensitivities to cancer therapies, identify novel cancer vulnerabilities, and understand the basis of therapy resistance, with an initial focus on ovarian cancer.
Her program has recently expanded into Women’s Health, applying the same human cellular models to the ovary and fallopian tube themselves. Female reproductive organs cycle, remodel, and age decades ahead of other tissues, with systemic effects during peri- and post-menopause. Yet they remain critically understudied. Her research is extending this platform to understand how these tissues age and why they are especially vulnerable to the effects of cancer treatments and other common drugs, with the long-term aim of identifying how the earliest pre-cancerous changes arise in these tissues.
Aging is the single greatest risk factor for cancer, and understanding how reproductive tissues change over a lifetime opens opportunities for early detection and prevention, for assessing how drugs and other interventions affect these tissues, and for healthy aging in women more broadly.